Effects of Mutations in the G Tract of the Human Immunodeficiency Virus Type 1 Polypurine Tract on Virus Replication and RNase H Cleavage
Overview
Authors
Affiliations
The RNase H cleavages that generate and remove the polypurine tract (PPT) primer during retroviral reverse transcription must be specific in order to create a linear viral DNA that is suitable for integration. Lentiviruses contain a highly conserved sequence consisting of six guanine residues at the 3' end of the PPT (hereafter referred to as the G tract). We introduced mutations into the G tract of a human immunodeficiency virus type 1-based vector and determined the effects on the virus titer and RNase H cleavage specificity. Most mutations in the G tract had little or no effect on the virus titer. Mutations at the second and fifth positions of the G tract increased the proportion of two-long-terminal-repeat (2-LTR) circle junctions with one or two nucleotide insertions. The second and fifth positions of the G tract make specific contacts with amino acids in the RNase H domain that are important for RNase H cleavage specificity. These complementary data define protein-nucleic acid interactions that help control the specificity of RNase H cleavage. When the G-tract mutants were analyzed in a viral background that was deficient in integrase, in most cases the proportion of consensus 2-LTR circle junctions increased. However, in the case of a mutant with Ts at the second and fifth positions of the G tract, the proportion of 2-LTR circle junctions containing the one-nucleotide insertion increased, suggesting that linear viral DNAs containing an extra base are substrates for integration. This result is consistent with the idea that the 3' end-processing reactions of retroviral integrases may help to generate defined ends from a heterogenous population of linear viral DNAs.
Wei X, Lipscomb J, Tino A, Cong M, Ruone S, Bentz M Viruses. 2025; 16(12.
PMID: 39772184 PMC: 11680205. DOI: 10.3390/v16121874.
HIV ribonuclease H: continuing the search for small molecule antagonists.
Wendeler M, Beilhartz G, Beutler J, Gotte M, Le Grice S HIV Ther. 2024; 3(1):39-53.
PMID: 38961883 PMC: 11221599. DOI: 10.2217/17584310.3.1.39.
Dekker J, Klaver B, Berkhout B, Das A J Virol. 2023; 97(5):e0036123.
PMID: 37125907 PMC: 10231180. DOI: 10.1128/jvi.00361-23.
Identification of an integrase-independent pathway of retrotransposition.
Li F, Lee M, Esnault C, Wendover K, Guo Y, Atkins P Sci Adv. 2022; 8(26):eabm9390.
PMID: 35767609 PMC: 11042837. DOI: 10.1126/sciadv.abm9390.
Hachiya A, Kubota M, Shigemi U, Ode H, Yokomaku Y, Kirby K J Antimicrob Chemother. 2021; 77(3):574-577.
PMID: 34894227 PMC: 8865006. DOI: 10.1093/jac/dkab448.